Shares of Innocan Pharma Corporation (OTCMKTS:INNPF) (CSE:INNO) have been moving within a narrow range. The stock has lost 24% in the past month.
Trading Data
On Friday, INNO stock went up 37.50% to C$0.77 with more than 55 shares, compared to its average volume of 102K shares.
Innocan Pharma Releases Important Update about its LPT Platform Project
Innocan Pharma Corporation (OTCMKTS:INNPF) (CSE:INNO) has provided an important update regarding its research into CBD loaded liposomes using Innocan’s LPT platform. The objective of this research is to come up with a technology that combines benefits of two well-known drug and delivery system to create a novel drug product that can be used to treat a wide range of health problems therapeutically such as pain, multiple sclerosis, rheumatoid arthritis epilepsy and many other diseases.
The problem with CBD is that it breaks down quickly in the body and shows low and variable oral bioavailability. Thus it reduces any therapeutic effect. Innocan seeks to administer CBD encapsulated in liposomes (the LPT platform), in order to construct long-lasting significant levels of CBD in the body. It is believed to create a far more effective and continuous therapeutic effect.
Initial results of experiments of its LPT platform on animals, back in 2021, have shown positive results. The latest study has shown that CBD encapsulated in liposomes can be detected in sufficient quantities for up to 6 weeks following a single administration. Many more studies are set to be conducted in 2022, which will shed further light on this matter.
Innocan Israel has also entered into the Research and License Agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, for the design, preparation, characterization and evaluation of CBD (or other cannabinoids) loaded liposomes.
Key Quote
Iris Bincovich, Innocan Pharma’s CEO, commented, “We are excited about our ability to encapsulate CBD molecules in liposomes. The encapsulation process is a difficult task, and we are pleased with the initial results. The ability to create prolonged release of the CBD, while keeping therapeutic levels in the tissue/blood may open up the LPT technology for uses in a wide variety of clinical indications.”
Technical Data
INNO stock is trading above the 20-Day and 200-Day Moving averages of $0.67 and $0.69 respectively. Moreover, the stock is below 50-Day moving average of $0.9.
